TP53 and acute myeloid leukemia: Magrolimab was tested in association with azacitidine in a phase 1b study in AML patients unfit for intensive chemotherapy, showing a promising CR rate above 40%, also in TP53-mutated AML, and no immune-related adverse events were observed [198].